Jefferies Financial Group Inc. Takes $4.60 Million Position in Mirum Pharmaceuticals, Inc. $MIRM

Jefferies Financial Group Inc. bought a new position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 39,260 shares of the company’s stock, valued at approximately $4,596,000. Jefferies Financial Group Inc. owned 0.06% of Mirum Pharmaceuticals as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Jupiter Topco LLC acquired a new position in Mirum Pharmaceuticals in the 2nd quarter valued at $691,672,000. BlackRock Inc. acquired a new stake in shares of Mirum Pharmaceuticals in the second quarter valued at about $513,945,000. William Blair Investment Management LLC bought a new position in shares of Mirum Pharmaceuticals in the second quarter worth about $164,453,000. Janus Henderson Group PLC increased its stake in shares of Mirum Pharmaceuticals by 21.4% in the fourth quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company’s stock worth $479,050,000 after purchasing an additional 1,067,722 shares during the period. Finally, State Street Corp lifted its position in shares of Mirum Pharmaceuticals by 59.2% during the 4th quarter. State Street Corp now owns 2,143,992 shares of the company’s stock worth $169,354,000 after purchasing an additional 797,088 shares during the last quarter.

Insider Transactions at Mirum Pharmaceuticals

In related news, SVP Jolanda Howe sold 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $100.00, for a total transaction of $4,000,000.00. Following the completion of the transaction, the senior vice president owned 1,274 shares in the company, valued at $127,400. This trade represents a 96.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Christopher Peetz sold 30,000 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $95.84, for a total value of $2,875,200.00. Following the completion of the sale, the chief executive officer directly owned 194,309 shares in the company, valued at approximately $18,622,574.56. This represents a 13.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 133,156 shares of company stock valued at $13,763,562. Corporate insiders own 8.32% of the company’s stock.

Mirum Pharmaceuticals Trading Down 2.3%

Shares of Mirum Pharmaceuticals stock opened at $97.46 on Friday. Mirum Pharmaceuticals, Inc. has a 52-week low of $63.23 and a 52-week high of $130.00. The firm has a market capitalization of $6.33 billion, a PE ratio of -6.70 and a beta of 0.52. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.86 and a quick ratio of 2.74. The company’s fifty day moving average price is $110.63 and its two-hundred day moving average price is $101.79.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.32). The business had revenue of $176.24 million for the quarter, compared to analyst estimates of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. Mirum Pharmaceuticals’s revenue was up 37.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.12) earnings per share. On average, analysts expect that Mirum Pharmaceuticals, Inc. will post -1.31 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Citigroup reaffirmed a “market outperform” rating on shares of Mirum Pharmaceuticals in a research report on Thursday. Wall Street Zen upgraded shares of Mirum Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. Raymond James Financial reissued a “strong-buy” rating and issued a $165.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. TD Cowen decreased their price target on shares of Mirum Pharmaceuticals from $145.00 to $140.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Finally, CLSA set a $146.00 price objective on shares of Mirum Pharmaceuticals in a research report on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $137.31.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.